Table 2.
Above target |
Outside targeta |
|||||||
---|---|---|---|---|---|---|---|---|
CKD-MBD composite score | Overall | USA | Canada | Europe | Overall | USA | Canada | Europe |
No. of patients | 12 235 | 7577 | 580 | 4078 | 19 313 | 10 699 | 1046 | 7568 |
| ||||||||
MBD 0 | 55 | 54 | 50 | 56 | 35 | 39 | 28 | 30 |
MBD 1 | 34 | 33 | 35 | 35 | 41 | 40 | 43 | 44 |
PTH | 24 | 23 | 37 | 23 | 39 | 33 | 49 | 45 |
Ca | 4 | 3 | 2 | 6 | 14 | 15 | 16 | 13 |
P | 72 | 74 | 61 | 71 | 47 | 52 | 35 | 41 |
MBD 2 | 11 | 12 | 14 | 10 | 21 | 19 | 24 | 23 |
PTH, P | 88 | 90 | 89 | 83 | 61 | 60 | 56 | 62 |
PTH, Ca | 4 | 3 | 9 | 5 | 14 | 11 | 21 | 15 |
P, Ca | 8 | 7 | 3 | 12 | 25 | 28 | 24 | 22 |
MBD 3 | 1 | 1 | 1 | 1 | 4 | 3 | 5 | 4 |
Values indicate % of patients (for MBD rows) or % of patients in group (MBD 1 and MBD 2 subdistributions). Subdistributions for MBD 1 and MBD 2 indicate which CKD-MBD markers are above or outside target. Europe includes Belgium, France, Germany, Italy, Spain, Sweden and the UK. CKD-MBD marker targets used: PTH, 150–600 pg/mL; Ca, 8.4–10.2 mg/dL; P, 3.5–5.5 mg/dL.
Sensitivity analysis.